When the National Wilma Tumor Study Group, the Intergroup Rhabdomyosarcoma Study Group, the Pediatric Oncology Group, and the Children's Cancer Group merged in 2000, it gave the newly formed Children's Oncology Group a chance to investigate uncommon cancers that had not been the subject of organized evaluation within the framework of a cooperative group. The rare tumor committee was established by the COG in 2002 and consists of four subcommittees. The brief tumor subcommittee's period of experience is described in this article. We have observed low registration rates within the COG registry and low participation rates in open banking, biology, and first-line therapeutic studies during the initial implementation of this strategy. We have been able to come up with new ways to increase clinical trial enrolment and registration rates thanks to this initial experience. With these new plans, it is hoped that we will be able to learn more about the biology of young patients with rare cancers and improve their treatment outcomes. Additionally, our initial experience has demonstrated the potential strength of global cooperation and collaboration.
Published Date: 2023-02-23; Received Date: 2023-01-28
